Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Retained Earnings (2016 - 2026)

Corvus Pharmaceuticals' Retained Earnings history spans 12 years, with the latest figure at -$426.0 million for Q1 2026.

  • Quarterly Retained Earnings fell 11.57% to -$426.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$426.0 million through Mar 2026, down 11.57% year-over-year, with the annual reading at -$896000.0 for FY2025, 30.43% up from the prior year.
  • Retained Earnings came in at -$426.0 million for Q1 2026, down from -$896000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$738000.0 in Q3 2024 to a low of -$426.0 million in Q1 2026.
  • The 5-year median for Retained Earnings is -$315.6 million (2023), against an average of -$260.2 million.
  • Year-over-year, Retained Earnings crashed 331037.35% in 2022 and then surged 99.62% in 2024.
  • Corvus Pharmaceuticals' Retained Earnings stood at -$307.7 million in 2022, then decreased by 8.78% to -$334.7 million in 2023, then soared by 99.62% to -$1.3 million in 2024, then soared by 30.43% to -$896000.0 in 2025, then plummeted by 47442.97% to -$426.0 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Retained Earnings are -$426.0 million (Q1 2026), -$896000.0 (Q4 2025), and -$400.0 million (Q3 2025).